Proactive Investors - Run By Investors For Investors

Cellmid builds IP for midkine portfolio with new patents

The company's patent portfolio comprises 60 patents and applications in 13 patent families.
folder labeled Patents
Detecting midkine in adults can be used as an indicator for detecting diseases

Cellmid Ltd (ASX:CDY) has strengthened and secured the intellectual property (IP) in its midkine antibodies portfolio after being granted a US patent and advancing a European patent.

The US Patent Office granted the patent application entitled "Antibody recognizing N-domain of midkine".

In addition, Cellmid received a ‘Notification of Intention to Grant’ from the European Patent Office for the corresponding patent in key European territories.

READ: Cellmid launches évolis® Professional products in 17 store locations across the US

The newly granted midkine antibody patents and allied patent families underpin the company’s dominant IP position over the use of therapeutic midkine antibodies for the treatment of diseases.

These diseases arise from cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune diseases.

Midkine is an important early marker for diagnosing diseases

Midkine is a growth factor that is highly expressed during embryonic development.

It modulates many important biological interactions such as cell growth that are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing.

Midkine is barely detectable in healthy adults midkine expression is often evident very early in disease onset, even before any apparent physical symptoms.

Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases.

Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use